Brokerages Expect Conatus Pharmaceuticals Inc (CNAT) Will Announce Quarterly Sales of $9.70 Million
Wall Street brokerages expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce sales of $9.70 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from $7.95 million to $11.75 million. Conatus Pharmaceuticals reported sales of $9.57 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.4%. The business is expected to announce its next earnings results on Wednesday, November 7th.
On average, analysts expect that Conatus Pharmaceuticals will report full-year sales of $36.86 million for the current financial year, with estimates ranging from $32.59 million to $38.51 million. For the next financial year, analysts forecast that the company will report sales of $46.27 million, with estimates ranging from $27.65 million to $75.44 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. The company had revenue of $8.77 million during the quarter, compared to analysts’ expectations of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%.
Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Conatus Pharmaceuticals during the 2nd quarter worth approximately $142,000. Paloma Partners Management Co purchased a new position in Conatus Pharmaceuticals in the second quarter valued at approximately $547,000. Bank of America Corp DE lifted its stake in Conatus Pharmaceuticals by 75.7% in the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after purchasing an additional 60,604 shares during the last quarter. Alambic Investment Management L.P. lifted its stake in Conatus Pharmaceuticals by 207.0% in the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock valued at $1,133,000 after purchasing an additional 178,461 shares during the last quarter. Finally, MYDA Advisors LLC purchased a new position in Conatus Pharmaceuticals in the second quarter valued at approximately $154,000. Hedge funds and other institutional investors own 33.50% of the company’s stock.
Shares of NASDAQ CNAT traded up $0.11 during midday trading on Friday, reaching $4.77. The company had a trading volume of 383,900 shares, compared to its average volume of 608,523. The stock has a market cap of $155.55 million, a P/E ratio of -7.87 and a beta of 1.38. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
See Also: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.